BOSULIF® is indicated for the treatment of adult patients with:

  • Newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).
  • CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

BOSULIF® (bosutinib) Summary of Product Characteristics

Legal Category: S1A
Date of Preparation May 2022